jiac153.pdf
591.3 KB
Oxford Journal of Infectious Diseases (November 2022 issue Drop 2 of 2)
Something else I noticed about this issue, was the amount of truly interesting papers, that were denied access to the general public by an academic institution wall, that was far more than usual around 20 in total?
1) Hamsters Protected from SARS-CoV-2 Delta Variant Challenge after Two Doses of Adjuvanted SARS-CoV-2 Recombinant Spike Protein (S-2P) and One Dose of Beta S-2P
2) SARS-CoV-2 Infection Causes Hyperglycemia in Cats
3) Nucleocapsid Antigenemia Is a Marker of Acute SARS-CoV-2 Infection
4) Breakthrough Gastrointestinal COVID-19 and Intrahost Evolution Consequent to Combination Monoclonal Antibody Prophylaxis
5) Global Prevalence of Post-Coronavirus Disease 2019 (COVID-19) Condition or Long COVID: A Meta-Analysis and Systematic Review
6) Low Risk of Severe Acute Respiratory Syndrome Coronavirus 2 Transmission by Fomites: A Clinical Observational Study in Highly Infectious Coronavirus Disease 2019 Patients
Something else I noticed about this issue, was the amount of truly interesting papers, that were denied access to the general public by an academic institution wall, that was far more than usual around 20 in total?
1) Hamsters Protected from SARS-CoV-2 Delta Variant Challenge after Two Doses of Adjuvanted SARS-CoV-2 Recombinant Spike Protein (S-2P) and One Dose of Beta S-2P
2) SARS-CoV-2 Infection Causes Hyperglycemia in Cats
3) Nucleocapsid Antigenemia Is a Marker of Acute SARS-CoV-2 Infection
4) Breakthrough Gastrointestinal COVID-19 and Intrahost Evolution Consequent to Combination Monoclonal Antibody Prophylaxis
5) Global Prevalence of Post-Coronavirus Disease 2019 (COVID-19) Condition or Long COVID: A Meta-Analysis and Systematic Review
6) Low Risk of Severe Acute Respiratory Syndrome Coronavirus 2 Transmission by Fomites: A Clinical Observational Study in Highly Infectious Coronavirus Disease 2019 Patients
212373481.pdf
2.6 MB
Virus Replicon Particle Vaccines (VRPV's): The forgotten alternative technology for gene based vaccine / treatment delivery.
In this drop are a series of papers on Virus Replicon Particle Vaccines (VRPV's) and their continued use / experimentation, as a vaccine delivery system and the vector that was favoured by Johnson & Johnson and AstraZeneca.
These use a viral outer shell, instead of a synthetic lipid nanoparticle, to encapsulate the mRNA / mDNA and deliver it into the body and is seen as a more natural and likely far more successful delivery system, specifically with regards to mDNA (modified, also referred to as Recombinant, DNA) based technologies.
These mDNA based vaccines, are already in circulation btw, as it was mDNA that AZ used, with J&J opting for using mRNA in their VRPV technology.
In this drop are a series of papers on Virus Replicon Particle Vaccines (VRPV's) and their continued use / experimentation, as a vaccine delivery system and the vector that was favoured by Johnson & Johnson and AstraZeneca.
These use a viral outer shell, instead of a synthetic lipid nanoparticle, to encapsulate the mRNA / mDNA and deliver it into the body and is seen as a more natural and likely far more successful delivery system, specifically with regards to mDNA (modified, also referred to as Recombinant, DNA) based technologies.
These mDNA based vaccines, are already in circulation btw, as it was mDNA that AZ used, with J&J opting for using mRNA in their VRPV technology.
nanomedicines-to-overcome-biological-barriers.pdf
3.7 MB
Lipid Nano Particle technology: How they're made, what they're made from and everything else you wanted to know, but didn't know who to ask? (Drop 1 of 2)
In this 2 part drop we will examine what goes into the manufacturing of the Lipid Nano Particle technology, that is famously used in the mRNA vaccines. This will look at ever facet of LNP production, from it's research and development, different types developed and researched and which of those types are still in use?
Also the manufacturing process and what exactly they're made of?
All told by some actual experts in this area, an actual LNP manufacturing company, through a dedicated cross company communications portal:
Nano-medicines: The power of particles
This should help you understand, not only how LNP's work and but also how they're made?
In this 2 part drop we will examine what goes into the manufacturing of the Lipid Nano Particle technology, that is famously used in the mRNA vaccines. This will look at ever facet of LNP production, from it's research and development, different types developed and researched and which of those types are still in use?
Also the manufacturing process and what exactly they're made of?
All told by some actual experts in this area, an actual LNP manufacturing company, through a dedicated cross company communications portal:
Nano-medicines: The power of particles
This should help you understand, not only how LNP's work and but also how they're made?
polymer-based-nanocomplexes-modified-2.pdf
3.3 MB
Lipid Nano Particle technology: How they're made, what they're made from and everything else you wanted to know, but didn't know who to ask? (Drop 2 of 2)
In this 2nd and final drop on LNP's, you will find a full glossary of terminology used when referring to LNP's (so you too can sound like a seasoned veteran, in the LNP tech field) but also a very helpful Q&A session, held by the manufacturers themselves, answering some of the more pressing questions, surrounding the LNP tech. A definite, ask the experts, session that everyone should find extremely helpful.
In this 2nd and final drop on LNP's, you will find a full glossary of terminology used when referring to LNP's (so you too can sound like a seasoned veteran, in the LNP tech field) but also a very helpful Q&A session, held by the manufacturers themselves, answering some of the more pressing questions, surrounding the LNP tech. A definite, ask the experts, session that everyone should find extremely helpful.